Analyst Ratings For Allergy Therapeutics plc (LON:AGY)
Today, FinnCap reiterated its Buy rating on Allergy Therapeutics plc (LON:AGY) with a price target of GBX 43.
There are 4 buy ratings on the stock.
The current consensus rating on Allergy Therapeutics plc (LON:AGY) is Buy (Score: 3.00) with a consensus target price of GBX 48.25 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-FinnCap Reiterated Rating of Buy.
- 2/14/2017-Panmure Gordon Reiterated Rating of Buy.
- 2/14/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 1/19/2017-Numis Securities Ltd Reiterated Rating of Buy.
About Allergy Therapeutics plc (LON:AGY)
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.
Recent Trading Activity for Allergy Therapeutics plc (LON:AGY)
Shares of Allergy Therapeutics plc closed the previous trading session at 25.75 up +0.50 1.98% with 0 shares trading hands.